Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a report issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

ATHX stock opened at $0.01 on Friday. Athersys has a 1 year low of $0.01 and a 1 year high of $1.99. The company has a market cap of $370,314.00, a P/E ratio of 0.00 and a beta of -0.90. The firm has a 50-day moving average of $0.01 and a 200 day moving average of $0.05.

Hedge Funds Weigh In On Athersys

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Athersys by 9.0% in the first quarter. Vanguard Group Inc. now owns 10,986,945 shares of the biopharmaceutical company’s stock worth $6,652,000 after buying an additional 910,501 shares in the last quarter. State Street Corp grew its holdings in Athersys by 5.6% in the first quarter. State Street Corp now owns 3,781,384 shares of the biopharmaceutical company’s stock worth $2,290,000 after purchasing an additional 201,070 shares during the period. JPMorgan Chase & Co. grew its holdings in Athersys by 37.6% in the second quarter. JPMorgan Chase & Co. now owns 3,155,103 shares of the biopharmaceutical company’s stock worth $820,000 after purchasing an additional 861,475 shares during the period. Millennium Management LLC grew its holdings in Athersys by 381.8% in the second quarter. Millennium Management LLC now owns 2,317,856 shares of the biopharmaceutical company’s stock worth $603,000 after purchasing an additional 1,836,746 shares during the period. Finally, UBS Group AG grew its holdings in Athersys by 30.1% in the second quarter. UBS Group AG now owns 724,652 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 167,756 shares during the period. 19.35% of the stock is owned by institutional investors.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.